Harmony Biosciences Holdings, Inc.

NASDAQ•HRMY

CEO: Mr. Jeffrey S. Aronin

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2020-08-19

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Contact Information

630 West Germantown Pike, Suite 215, Plymouth Meeting, PA, 19462, United States

484-539-9800

www.harmonybiosciences.com

Market Cap

$1.66B

P/E (TTM)

10.4

17.5

Dividend Yield

52W High

$40.87

52W Low

$25.52

52W Range

21%

Rank37Top 34.1%

4.4

F-Score

Modified Piotroski Analysis

Based on 7-year fundamentals

Average • 4.4 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2019-2025

Financial Dashboard

Q4 2025 Data

Revenue

$243.78M+0.00%

4-Quarter Trend

EPS

$0.39+0.00%

4-Quarter Trend

FCF

$126.04M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

WAKIX Revenue Growth Net product revenue reached $868.5 M in 2025, marking a 21.5% increase driven by unit volume growth and price realization.

Net Income Improvement Net income totaled $158.7 M for 2025, reflecting strong operational leverage compared to $145.5 M reported in 2024.

R&D Investment Surge Research and development expenses grew 30.0% to $189.6 M, funding pipeline expansion across multiple franchises including EPX-100.

Strong Cash Position Cash, equivalents, and investments totaled $882.5 M as of year-end 2025, supporting ongoing operations and future investing activities.

Risk Factors

Single Product Revenue Reliance Business success substantially depends on WAKIX commercial performance; failure to maintain or increase sales adversely affects financial condition.

License Agreement Dependency Reliance on Bioprojet license for pitolisant IP; termination or loss of significant rights severely impacts development and commercialization efforts.

Competitive Generic Entry Intense industry competition and potential generic versions could materially reduce market share and profitability for WAKIX and future products.

Regulatory Approval Uncertainty FDA approval process remains costly, lengthy, and unpredictable, potentially delaying or preventing commercialization of pipeline assets in other indications.

Outlook

Next-Gen Pitolisant Advancement Pitolisant GR targets NDA submission in Q1 2026 following positive bioequivalence data; HD Phase 3 trials are now initiated.

Pipeline Expansion Focus Advancing rare epilepsy assets EPX-100 (Phase 3) and new CNS fatigue formulation development toward a Phase 1 PK study.

Securing Pediatric Exclusivity Initiating PWS Phase 3 TEMPO study supports efforts to obtain crucial pediatric exclusivity for the WAKIX label expansion.

Peer Comparison

Revenue (TTM)

NVAX

$1.12B

+64.7%

HRMY

$868.45M

+21.5%

IMCR

$372.97M

+20.2%

Gross Margin (Latest Quarter)

CLDX

100.0%

+0.0pp

ABCL

100.0%

+588.5pp

NUVB

99.0%

+182.9pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
EWTX	$3.14B	-18.0	-32.0%	0.7%
VERA	$2.87B	-8.6	-59.7%	10.5%
VRDN	$2.48B	-7.2	-58.4%	5.6%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

9.7%

Steady Growth

4Q Net Income CAGR

-21.0%

Declining Profitability

Cash Flow Stability

100%

Strong Cash Flow

Deep Research

Next earnings:May 4, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data